Hot Life Science Investor Mandate 2: PE Firm Seeking Novel Therapeutics, Diagnostics, and Service Providers of All Stages

1 May

The life science venture investment arm of a leading global Private Equity firm with over $50 billion in AUM, is looking to make investments across development pipeline, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $50M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, personalized medicine, diagnostics, industrial biotechnology, healthcare services and IT. The firm does not invest in medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics. 

The firm invests for the long term, and are heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: